Core Viewpoint - The company reported a significant increase in total revenue and gross profit for the fiscal year ending December 31, 2025, indicating strong financial performance and recovery from previous losses [1] Financial Performance - Total revenue reached approximately RMB 2.618 billion, representing a year-on-year increase of about 37.7% [1] - Gross profit was approximately RMB 1.802 billion, showing a year-on-year increase of about 45.1% [1] - The profit attributable to the company's owners was approximately RMB 180 million, marking a turnaround from previous losses [1] - Basic earnings per share were reported at 1.97 cents [1] Research and Development Expenditure - Overall research and development expenses amounted to approximately RMB 291 million, reflecting a year-on-year decrease of 38.5% [1] Dividend Announcement - The company proposed a final dividend of 0.96 cents per share [1]
四环医药(00460.HK)发布年度业绩 股东应占溢利约1.8亿元 同比扭亏为盈